Abstract: CX-5461 (Pidnarulex) is a first-in-class, multi-targeted anticancer agent that has garnered significant attention for its potent anti-tumor properties and its emerging role in immuno-oncology. Initially characterized as a selective inhibitor of RNA polymerase I (Pol I) that disrupts ribosome biogenesis, CX-5461 is now recognized as a G-quadruplex (G4) stabilizer and a DNA structure-driven topoisomerase II (TOP II) poison. By inducing nucleolar stress, global replication stress, and the nucleolar DNA damage response (n-DDR), CX-5461 triggers cell cycle arrest, senescence, and apoptosis across various malignancies. Crucially, recent evidence highlights its potential in immuno-oncology combination therapies. CX-5461 promotes immunogenic cell death (ICD), activates the innate immune response via the cGAS-STING pathway, and modulates the PD-L1/PD-1 axis, thereby reprogramming immunosuppressive tumor microenvironments. Despite challenges such as poor aqueous solubility and dose-limiting photosensitivity, innovative nano-delivery systems and rational combination strategies—particularly with immune checkpoint inhibitors and DNA damage repair (DDR) inhibitors—position CX-5461 as a highly promising candidate for advanced cancer therapeutics.
1. Introduction
Ribosome biogenesis is a fundamental cellular process that is frequently hyperactivated in cancer cells to sustain their rapid growth and proliferation. Targeting this dependency has emerged as a viable therapeutic strategy. CX-5461, also known as Pidnarulex, is a first-in-class small-molecule anticancer drug that has received "Fast Track Designation" from the US FDA [1]. Originally discovered through a compound screen for selective inhibitors of RNA polymerase I (Pol I) transcription, CX-5461 was shown to disrupt the initiation stage of ribosomal RNA (rRNA) synthesis [1][2].
Over the past decade, the mechanistic understanding of CX-5461 has evolved significantly. Beyond Pol I inhibition, it is now established that CX-5461 acts as a potent stabilizer of DNA G-quadruplex (G4) structures and functions as a topoisomerase II (TOP II) poison [1][3]. This multifaceted mechanism of action induces profound DNA damage and replication stress, particularly in tumors with homologous recombination (HR) deficiencies, such as those harboring BRCA1/2 or PALB2 mutations [1]. Furthermore, recent preclinical investigations have illuminated the capacity of CX-5461 to modulate the tumor immune microenvironment, making it a compelling candidate for immuno-oncology combination therapies [1].
2. Pharmacological Activity
CX-5461 exhibits broad-spectrum pharmacological activity across a variety of malignancies, including acute myeloid leukemia (AML), lymphoma, multiple myeloma, breast cancer, prostate cancer, and high-grade serous ovarian cancer (HGSOC) [1][3][4]. It has also shown potential in combating tamoxifen resistance in estrogen receptor-positive (ER+ve) breast cancer by repressing c-MYC-driven ribosome biogenesis [5]. In clinical settings, Phase I trials have demonstrated its efficacy in patients with advanced hematologic malignancies and solid tumors enriched for DNA-repair deficiencies, yielding prolonged partial responses and stable disease [1][2].
Immuno-Oncology and Combination Therapy: A pivotal new research direction for CX-5461 lies in its immunomodulatory effects. CX-5461 induces tumor-selective cytotoxicity while simultaneously reprogramming immunosuppressive niches [1]. It triggers immunogenic cell death (ICD) by activating the retinoic acid-induced gene I (RIG-I) pathway, leading to the cytosolic release of damage-associated molecular patterns (DAMPs) such as ATP and HMGB1, which prime cytotoxic T-cell responses [1]. Additionally, CX-5461 induces the accumulation of cytosolic double-stranded DNA (dsDNA), which activates the cGAS-STING innate immune pathway. This activation leads to IRF3 phosphorylation and the robust upregulation of pro-inflammatory cytokines and chemokines, including CXCL10, IL-6, IFN-α/β, and CCL5 [1].
Importantly, CX-5461 has been found to upregulate PD-L1 expression through STAT1 activation in colorectal and breast cancer models [1]. While this represents a compensatory immune evasion mechanism by the tumor, it creates a distinct therapeutic vulnerability. Consequently, combining CX-5461 with PD-1/PD-L1 immune checkpoint blockade has demonstrated synergistic tumor growth suppression in preclinical models, highlighting its immense potential in immuno-oncology combination regimens [1].
3. Molecular Mechanism of Action
The cytotoxicity of CX-5461 is driven by a complex, multi-targeted mechanism of action:
1. Inhibition of RNA Polymerase I (Pol I): CX-5461 selectively inhibits Pol I transcription by preventing the selectivity factor 1 (SL-1) complex from interacting with the rDNA promoter [2][3]. This disrupts the formation of the pre-initiation complex (PIC) and leads to nucleolar stress. In p53-wildtype cells, this stress causes the release of ribosomal proteins (e.g., RPL5 and RPL11), which sequester the E3 ubiquitin ligase MDM2, thereby stabilizing p53 and inducing apoptosis or cell cycle arrest [2][4]. In p53-null or mutated cells, CX-5461 activates a p53-independent nucleolar DNA damage response (n-DDR) mediated by ATM and ATR kinases, leading to G2/M cell cycle arrest [3][4].
2. G-Quadruplex (G4) Stabilization: CX-5461 binds to and stabilizes G4 structures within the genome, particularly at telomeric ends and the promoter regions of oncogenes such as c-MYC and c-KIT1 [1]. The stabilization of these structures impedes DNA replication and transcription, leading to the formation of R-loops, global replication stress, and the generation of DNA double-strand breaks (DSBs) [1][3].
3. Topoisomerase II (TOP II) Poisoning: CX-5461 acts as a DNA structure-driven TOP II poison. The stabilization of G4s at transcriptionally active loci causes RNA polymerase stasis, which mobilizes TOP II to resolve the resulting topological stress. CX-5461 traps TOP II at these sites (specifically TOP IIα and TOP IIβ), resulting in the accumulation of cytotoxic DSBs [1][3]. This mechanism is distinct from classical TOP II inhibitors like etoposide [1].
4. Structure-Activity Relationship (SAR)
CX-5461 is a derivative of the fluoroquinolone A-62176, a known topoisomerase II poison [1]. While detailed SAR studies are limited in the provided literature, its structural features dictate its binding preferences. CX-5461 interacts with G4 structures primarily through π-π stacking interactions between its hetero-aromatic moieties and the planar G-quartets of the DNA [1]. In vitro molecular dynamics and single-molecule magnetic tweezer experiments reveal that CX-5461 exhibits a substrate preference, showing the highest stabilizing effect on human telomeric G4s, followed by c-KIT1 and c-MYC G4s [1]. For the c-MYC G4, CX-5461 acts as a stabilizer that reduces the unfolding rate of the structure, binding at the 5'-end in a 1:1 ratio and occupying both the 5' and 3'-ends in a 2:1 ratio [1].
5. Current Limitations
Despite its therapeutic promise, the clinical translation of CX-5461 faces several significant limitations:
1. Physicochemical and Pharmacokinetic Challenges: CX-5461 exhibits poor aqueous solubility at physiological pH. It is currently administered intravenously or orally at a low pH (dissolved in 50 mM NaH2PO4, pH 4.5) [1]. Relying on a low pH formulation adversely affects its pharmacokinetics, biodistribution, and overall therapeutic potential [1].
2. Off-Target Effects and Toxicity: At micromolar concentrations, CX-5461 can non-selectively intercalate into double-stranded DNA (dsDNA) with high affinity, similar to ethidium bromide, which may induce non-specific cytotoxicity [1]. Clinically, it is associated with dose-independent dermatologic adverse events, notably photosensitivity and palmar-plantar erythrodysesthesia [1]. Furthermore, because it acts as a TOP II poison, there is a theoretical risk of therapy-induced acute leukemias or cardiotoxicity, which requires strict monitoring [1].
3. Resistance Mechanisms: Acquired resistance to CX-5461 has been observed in clinical trials, particularly through the emergence of reversion mutations in HR-related genes such as PALB2 and BRCA2, which restore DNA repair capacity and negate the synthetic lethality exploited by the drug [1].
6. Future Perspectives
To overcome current limitations and maximize the clinical utility of CX-5461, future research is heavily focused on advanced delivery systems and rational combination therapies.
Nano-Delivery Strategies: Nanotechnology offers a robust solution to CX-5461's solubility and toxicity issues. Formulations such as copper-complexed CX-5461 in liposomes (DMPC/Chol-Cu-CX-5461) have improved its apparent solubility by over 500-fold at neutral pH [1]. Other innovative platforms include Sophora Flavescens-derived exosome-like nanovesicles (SFELNVs) for oral delivery, and mesoporous silica nanoparticles (MSNs) conjugated with the AS1411 aptamer (which targets nucleolin) to achieve active, tumor-specific targeting while mitigating photosensitivity [1].
Individualized G4-Targeting: Because the human genome contains hundreds of thousands of G4s, non-selective G4 stabilization can lead to collateral mutagenesis. Future strategies propose coupling CX-5461 with nucleic acid sequence readers, such as peptide nucleic acids (PNAs) or locked nucleic acids (LNAs), to create dual-targeting molecules that recognize both the G4 structure and its specific flanking sequences, thereby achieving individualized G4 targeting [1].
Immuno-Oncology and Synergistic Combinations: The most promising clinical trajectory for CX-5461 is its integration into immuno-oncology regimens. Given its ability to activate the cGAS-STING pathway and upregulate PD-L1, combining CX-5461 with PD-1/PD-L1 inhibitors is a highly rational approach to overcome immune evasion [1]. Additionally, exploiting synthetic lethality by combining CX-5461 with PARP inhibitors (e.g., olaparib), TOP1 inhibitors (e.g., topotecan), or inhibitors of the PI3K/AKT/mTOR and PIM kinase pathways holds great potential for treating refractory, HR-deficient, and MYC-driven cancers [2][3][4].
